Effector Therapeutics Inc (EFTR) — Capital Reinvestment Ratio
Latest as of December 2020:
0.01x
Effector Therapeutics Inc (EFTR) has a Capital Reinvestment Ratio of 0.01x as of December 2020, meaning it reinvests 0% of its operating cash flow ($13.84 Million) in capital expenditures ($154.00K). See EFTR free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.01x
Capex / Operating Cash Flow
Operating Cash Flow
$13.84 Million
USD
Capital Expenditures
$154.00K
USD
Data as of
Dec 2020
Most recent filing
Effector Therapeutics Inc Capital Reinvestment Ratio (2020–2020)
This chart tracks Effector Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Effector Therapeutics Inc (2020–2020)
Year-by-year Capital Reinvestment Ratio for Effector Therapeutics Inc from 2020 to 2020. For live market cap and broader valuation context, see EFTR stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2020 | 0.01x | $13.84 Million | $154.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow